Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: A mini review

Journal of Neuroscience Methods

Volumn 233, Issue , 2014, Pages 166-171

  Kuo, Andy ^a   Smith, Maree T ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Brain; Central nervous system; Cerebrospinal fluid (CSF); Intracerebroventricular; Intrathecal; Rat; Supraspinal

Indexed keywords

NEW DRUG; CENTRAL NERVOUS SYSTEM AGENTS;

BEHAVIOR CHANGE; BLOOD BRAIN BARRIER; BRAIN AQUEDUCT; BRAIN FUNCTION; BRAIN INTERVENTRICULAR FORAMEN; BRAIN REGION; BRAIN THIRD VENTRICLE; CANNULA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID FLOW; CHOROID PLEXUS; CLINICAL STUDY; DEPRESSION; DRUG DIFFUSION; DRUG METABOLISM; EXTRACELLULAR FLUID; EXTRACELLULAR SPACE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRACRANIAL PRESSURE; INTRATHECAL DRUG ADMINISTRATION; LATERAL BRAIN VENTRICLE; MICROCIRCULATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SCHIZOPHRENIA; SUBARACHNOID SPACE; TRANSLATIONAL RESEARCH; VALIDITY; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROSPINAL FLUID; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; INDWELLING CATHETER; PROCEDURES;

ANIMALS; CATHETERS, INDWELLING; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROSPINAL FLUID; DRUG DISCOVERY; HUMANS; INFUSIONS, INTRAVENTRICULAR;

EID: 84903889142     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2014.06.006     Document Type: Review

References (76)

1. Adler T.K. Comparative potencies of codeine and its demethylated metabolites after intraventricular injection in the mouse. J Pharmacol Exp Ther 1963, 140:155-161.
2. Alavijeh M.S., Chishty M., Qaiser M.Z., Palmer A.M. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2005, 2:554-571.
3. Alonso J., Petukhova M., Vilagut G., Chatterji S., Heeringa S., Ustun T.B., et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry 2011, 16:1234-1246.
4. Bechter K. The peripheral cerebrospinal fluid outflow pathway-physiology and pathophysiology of CSF recirculation: a review and hypothesis. Neurol Psychiatry Brain Res 2011, 17:51-66.
5. Bechter K., Reiber H., Herzog S., Fuchs D., Tumani H., Maxeiner H.G. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010, 44:321-330.
6. Blakemore W.F. The fate of escaped plasma protein after thermal necrosis of the rat brain: an electron microscope study. J Neuropathol Exp Neurol 1969, 28:139-152.
7. Blyth F.M., March L.M., Brnabic A.J., Jorm L.R., Williamson M., Cousins M.J. Chronic pain in Australia: a prevalence study. Pain 2001, 89:127-134.
8. Boulanger A., Clark A.J., Squire P., Cui E., Horbay G.L. Chronic pain in Canada: have we improved our management of chronic noncancer pain?. Pain Res Manag 2007, 12:39-47.
9. Bui J.D., Nammari D.R., Buckley D.L., Inglis B.A., Silver X.S., Mareci T.H., et al. In vivo dynamics and distribution of intracerebroventricularly administered gadodiamide, visualized by magnetic resonance imaging. Neuroscience 1999, 90:1115-1122.
10. Cao C., Matsumura K., Ozaki M., Watanabe Y. Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells. J Neurosci 1999, 19:716-725.
11. Carrupt P.A., Testa B., Bechalany A., el Tayar N., Descas P., Perrissoud D. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 1991, 34:1272-1275.
12. Cavanagh J.B. The proliferation of astrocytes around a needle wound in the rat brain. J Anat 1970, 106:471-487.
13. Chen C.P., Chen R.L., Preston J.E. The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma. Exp Gerontol 2012, 47:323-328.
14. Christy N.P., Fishman R.A. Studies of the blood-cerebrospinal fluid barrier to cortisol in the dog. J Clin Invest 1961, 40:1997-2006.
15. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., et al. Grand challenges in global mental health. Nature 2011, 475:27-30.
16. Cook A.M., Mieure K.D., Owen R.D., Pesaturo A.B., Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy 2009, 29:832-845.
17. Cserr H.F. Physiology of the choroid plexus. Physiol Rev 1971, 51:273-311.
18. de Lange E.C. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS 2013, 10:12.
19. de Moraes Vieira E.B., Garcia J.B., da Silva A.A., Mualem Araujo R.L., Jansen R.C. Prevalence, characteristics, and factors associated with chronic pain with and without neuropathic characteristics in Sao Luis, Brazil. J Pain Symptom Manag 2012, 44:239-251.
20. Di Terlizzi R., Platt S. The function, composition and analysis of cerebrospinal fluid in companion animals: Part I - Function and composition. Vet J 2006, 172:422-431.
21. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
22. Fujiki N., Yoshida Y., Ripley B., Mignot E., Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003, 26:953-959.
23. Gradinaru D., Minn A.L., Artur Y., Minn A., Heydel J.M. Drug metabolizing enzyme expression in rat choroid plexus: effects of in vivo xenobiotics treatment. Arch Toxicol 2009, 83:581-586.
24. Gustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21:718-779.
25. Hanna M.H., Peat S.J., Woodham M., Knibb A., Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 1990, 64:547-550.
26. Harifi G., Amine M., Ait Ouazar M., Boujemaoui A., Ouilki I., Rekkab I., et al. Prevalence of chronic pain with neuropathic characteristics in the Moroccan general population: a national survey. Pain Med 2013, 14:287-292.
27. Hurko O., Ryan J.L. Translational research in central nervous system drug discovery. NeuroRx 2005, 2:671-682.
28. Ishizaki J., Yokogawa K., Nakashima E., Ichimura F. Prediction of changes in the clinical pharmacokinetics of basic drugs on the basis of octanol-water partition coefficients. J Pharm Pharmacol 1997, 49:762-767.
29. Johanson C.E., Duncan J.A., Klinge P.M., Brinker T., Stopa E.G., Silverberg G.D. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res 2008, 5:10.
30. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010, 16:1210-1214.
31. Kawasaki H., Nakamura S., Takasaki K. Furosemide inhibits the centrally-mediated pressor response to clonidine in conscious, normotensive rats. Br J Pharmacol 1991, 104:629-632.
32. Kessler R.C., Heeringa S., Lakoma M.D., Petukhova M., Rupp A.E., Schoenbaum M., et al. Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. Am J Psychiatry 2008, 165:703-711.
33. Langley P.C. The prevalence, correlates and treatment of pain in the European Union. Curr Med Res Opin 2011, 27:463-480.
34. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011, 477:526-528.
35. Leighton G.E., Rodriguez R.E., Hill R.G., Hughes J. kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol 1988, 93:553-560.
36. Leow K.P., Smith M.T. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 1994, 54:1229-1236.
37. Lepine J.P., Briley M. The epidemiology of pain in depression. Hum Psychopharmacol 2004, 19(Suppl. 1):S3-S7.
38. Levinger I.M. The cerebral ventricles of the rat. J Anat 1971, 108:447-451.
39. Lowenstein P.R., Castro M.G. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?. Curr Gene Ther 2009, 9:368-374.
40. Luger T.J., Kathrein A., Rieger M., Lorenz I.H. Intracerebroventricular and intrathecal injectate spread in rats. Eur J Anaesthesiol 2005, 22:236-239.
41. Mika J., Zychowska M., Popiolek-Barczyk K., Rojewska E., Przewlocka B. Importance of glial activation in neuropathic pain. Eur J Pharmacol 2013, 716:106-119.
42. Millan M.J. Multiple opioid systems and pain. Pain 1986, 27:303-347.
43. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003, 6:252-273.
44. Nielsen C.K., Ross F.B., Lotfipour S., Saini K.S., Edwards S.R., Smith M.T. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007, 132:289-300.
45. Ohayon M.M., Stingl J.C. Prevalence and comorbidity of chronic pain in the German general population. J Psychiatr Res 2012, 46:444-450.
46. Okura T., Saito M., Nakanishi M., Komiyama N., Fujii A., Yamada S., et al. Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats. Br J Pharmacol 2003, 140:211-217.
47. Olesen J., Leonardi M. The burden of brain diseases in Europe. European J Neurol 2003, 10:471-477.
48. Onaivi E.S., Schanz N., Lin Z.C. Psychiatric disturbances regulate the innate immune system in CSF of conscious mice. Transl Psychiatry 2014, 4:e367.
49. Pardridge W.M. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011, 8:7.
50. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev 2010, 9:203-214.
51. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1989, Academic Press, New York. 2nd ed.
52. Payne R., Gradert T.L., Inturrisi C.E. Cerebrospinal fluid distribution of opioids after intraventricular & lumbar subarachnoid administration in sheep. Life Sci 1996, 59:1307-1321.
53. Pham T., Carrega L., Sauze N., Fund-Saunier O., Devaux C., Peragut J.C., et al. Supraspinal antinociceptive effects of mu and delta agonists involve modulation of adenosine uptake. Anesthesiology 2003, 98:459-464.
54. Poo M-m. Whereto the mega brain projects?. Natl Sci Rev 2014, 1:12-14.
55. Porreca F., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 1984, 230:341-348.
56. Preston J.E. Ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech 2001, 52:31-37.
57. Raffa R.B., Pergolizzi J.V. Intracerebroventricular opioids for intractable pain. Br J Clin Pharmacol 2012, 74:34-41.
58. Salak-Johnson J.L., McGlone J.J., Whisnant C.S., Norman R.L., Kraeling R.R. Intracerebroventricular porcine corticotropin-releasing hormone and cortisol effects on pig immune measures and behavior. Physiol Behav 1997, 61:15-23.
59. Sengupta P. A scientific review of age determination for a Laboratory rat: How old is it in comparison with human age?. Biomed Int 2012, 2:81-89.
60. Serot J.M., Bene M.C., Faure G.C. Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci 2003, 8:s515-s521.
61. Serot J.M., Bene M.C., Foliguet B., Faure G.C. Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathol 2000, 99:105-108.
62. Silva-Moreno A., Gonzalez-Espinosa C., Leon-Olea M., Cruz S.L. Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: correlation with mu-opioid receptor internalization. Eur J Pharmacol 2012, 674:239-247.
63. Smith G.D., Smith M.T. The excitatory behavioral and antianalgesic pharmacology of normorphine-3-glucuronide after intracerebroventricular administration to rats. J Pharmacol Exp Ther 1998, 285:1157-1162.
64. Smith M.T., Wright A.W., Williams B.E., Stuart G., Cramond T. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg 1999, 88:109-116.
65. Soni A. The five most costly conditions, 1996 and 2006: estimates for the U.S. Civilian Noninstitutionalized population. Agency for Healthcare Research and Quality 2009, http://meps.ahrq.gov/data_files/publications/st248/stat248.pdf [accessed on 27.06.2014].
66. Stoeckli E.T. What does the developing brain tell us about neural diseases?. Eur J Neurosci 2012, 35:1811-1817.
67. Suzuki H., Sawada Y., Sugiyama Y., Iga T., Hanano M. Saturable transport of cimetidine from cerebrospinal fluid to blood in rats. J Pharmacobiodyn 1985, 8:73-76.
68. Thomas J.E., Rosenwasser R.H. Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurgery 1999, 44:48-57. [discussion-8].
69. Torrance N., Smith B.H., Bennett M.I., Lee A.J. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006, 7:281-289.
70. Vuillemenot B.R., Kennedy D., Reed R.P., Boyd R.B., Butt M.T., Musson D.G., et al. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution. Toxicol Appl Pharmacol 2014, 277:49-57.
71. Wahlstrom A., Winblad B., Bixo M., Rane A. Human brain metabolism of morphine and naloxone. Pain 1988, 35:121-127.
72. Whittico M.T., Giacomini K.M. Cimetidine elimination from the cerebrospinal fluid of the rat. Pharm Res 1988, 5:628-633.
73. Witt K.A., Davis T.P. CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J 2006, 8:E76-E88.
74. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jonsson B., et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21:655-679.
75. Wood M. Drug distribution: less passive, more active?. Anesthesiology 1997, 87:1274-1276.
76. Woolf C.J. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011, 152:S2-S15.